Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Contributors:
      Lille Inflammation Research International Center - U 995 (LIRIC); Institut Pasteur de Lille; Pasteur Network (Réseau International des Instituts Pasteur)-Pasteur Network (Réseau International des Instituts Pasteur)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille); Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille); Mycologie moléculaire - Molecular Mycology; Institut Pasteur Paris (IP)-Centre National de la Recherche Scientifique (CNRS); Centre National de Référence Mycoses Invasives et Antifongiques - National Reference Center Invasive Mycoses & Antifungals (CNRMA); Institut Pasteur Paris (IP); Imagine - Institut des maladies génétiques (IMAGINE - U1163); Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM); Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS); Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille); This work was supported by internal funding “Fonds d’aide à l’émergence et à l’excellence du CHRU de Lille-Bonus H”.
    • بيانات النشر:
      CCSD
      BioMed Central
    • الموضوع:
      2018
    • Collection:
      Inserm: HAL (Institut national de la santé et de la recherche médicale)
    • نبذة مختصرة :
      International audience ; BACKGROUND: The use of isavuconazole is approved for the management of invasive aspergillosis and mucormycosis, only in adults, as no paediatric pharmacology studies have been reported to date. Very few paediatric cases have been published concerning the use of isavuconazole. Amphotericin B is the only antifungal agent recommended in paediatric mucormycosis, but adverse effects and especially nephrotoxicity, even with the liposomal formulation, could be problematic. In this context, the use of other antifungal molecules active on Mucorales becomes needful.METHODS: We describe a case of mucormycosis with rapid onset dissemination in a 3-year-old girl recently diagnosed with acute lymphocytic leukaemia. She was successfully treated with isavuconazole alone and then in combination with liposomal amphotericin B. Isavuconazole therapy was guided by therapeutic drug monitoring.CONCLUSIONS: This case offers new perspectives on the potential use of isavuconazole in children with mucormycosis, as an alternative or adjunct to liposomal amphotericin B.
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/30522521; PUBMED: 30522521; PUBMEDCENTRAL: PMC6282241
    • الرقم المعرف:
      10.1186/s40360-018-0273-7
    • الدخول الالكتروني :
      https://hal.univ-lille.fr/hal-02513581
      https://hal.univ-lille.fr/hal-02513581v1/document
      https://hal.univ-lille.fr/hal-02513581v1/file/s40360-018-0273-7.pdf
      https://doi.org/10.1186/s40360-018-0273-7
    • Rights:
      http://creativecommons.org/licenses/by/ ; info:eu-repo/semantics/OpenAccess
    • الرقم المعرف:
      edsbas.6725C236